» Articles » PMID: 26895998

Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis

Overview
Publisher Springer
Specialty General Medicine
Date 2016 Feb 21
PMID 26895998
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adults who require long-term anticoagulation with low-molecular-weight heparin (LMWH) such as cancer patients or the elderly may be at increased risk of fractures.

Objective: To determine the effects of LMWH therapy of at least 3 months' duration on fractures and bone mineral density (BMD) in non-pregnant adult populations.

Methods: We systematically reviewed electronic databases (e.g., MEDLINE, EMBASE), conferences and bibliographies until June 2015 and included comparative studies in non-pregnant adult populations that examined the effects of LMWH (≥3 months) on fractures and BMD. We synthesized evidence qualitatively and used random-effects meta-analysis to quantify the effect of LMWH on fractures.

Results: Sixteen articles reporting 14 studies were included: 10 clinical trials (n = 4865 participants) and four observational cohort studies (3 prospective, n = 221; 1 retrospective, n = 30). BMD and fractures were secondary outcomes in the majority of trials, while they were primary outcomes in the majority of observational studies. In participants with venous thromboembolism and underlying cardiovascular disease or cancer (5 RCTs, n = 2280), LMWH for 3-6 months did not increase the relative risk of all fractures at 6-12 months compared to unfractionated heparin, oral vitamin K antagonists or placebo [pooled risk ratio (RR) = 0.58, 95 % CI: 0.23-1.43; I(2) = 12.5 %]. No statistically significant increase in the risk of fractures at 6-12 months was found for cancer patients (RR = 1.08, 95 % CI: 0.31-3.75; I(2) = 4.4 %). Based on the data from two prospective cohort studies (n = 166), LMWH for 3-24 months decreased mean BMD by 2.8-4.8 % (depending on the BMD site) compared to mean BMD decreases of 1.2-2.5 % with oral vitamin K antagonists.

Conclusions: LMWH for 3-6 months may not increase the risk of fractures, but longer exposure for up to 24 months may adversely affect BMD. Clinicians should consider monitoring BMD in adults on long-term LMWH who are at increased risk of bone loss or fracture.

Citing Articles

Warfarin and heparin monitoring in antiphospholipid syndrome.

Mittal P, Sayar Z, Cohen H Hematology Am Soc Hematol Educ Program. 2024; 2024(1):192-199.

PMID: 39644000 PMC: 11665698. DOI: 10.1182/hematology.2024000547.


The correlation between transient osteoporosis of the hip and pregnancy: A review.

Galanis A, Dimopoulou S, Karampinas P, Vavourakis M, Papagrigorakis E, Sakellariou E Medicine (Baltimore). 2023; 102(41):e35475.

PMID: 37832084 PMC: 10578699. DOI: 10.1097/MD.0000000000035475.


Management of fracture risk in CKD-traditional and novel approaches.

Haarhaus M, Aaltonen L, Cejka D, Cozzolino M, de Jong R, DHaese P Clin Kidney J. 2023; 16(3):456-472.

PMID: 36865010 PMC: 9972845. DOI: 10.1093/ckj/sfac230.


A Total of 207 Days of Veno-Venous Extracorporeal Membrane Oxygenation Support for Severe COVID-19 Prior to Successful Lung Transplantation: A Case Report.

Naar J, Kruger A, Vondrakova D, Janotka M, Kubele J, Lischke R J Pers Med. 2022; 12(12).

PMID: 36556249 PMC: 9787659. DOI: 10.3390/jpm12122028.


Not Just Anticoagulation-New and Old Applications of Heparin.

Zang L, Zhu H, Wang K, Liu Y, Yu F, Zhao W Molecules. 2022; 27(20).

PMID: 36296562 PMC: 9609994. DOI: 10.3390/molecules27206968.


References
1.
Guyatt G, Akl E, Crowther M, Gutterman D, Schuunemann H . Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):7S-47S. PMC: 3278060. DOI: 10.1378/chest.1412S3. View

2.
Samama C, Boubli L, Coloby P, Debourdeau P, Gruel Y, Mariette C . Venous thromboembolism prophylaxis in patients undergoing abdominal or pelvic surgery for cancer--a real-world, prospective, observational French study: PRéOBS. Thromb Res. 2013; 133(6):985-92. DOI: 10.1016/j.thromres.2013.10.038. View

3.
Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

4.
Santamaria A, Juarez S, Reche A, Gomez-Outes A, Martinez-Gonzalez J, Fontcuberta J . Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int J Clin Pract. 2006; 60(5):518-25. DOI: 10.1111/j.1368-5031.2006.00947.x. View

5.
Nishiyama M, Itoh F, UJIIE A . Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol. 1997; 74(1):59-68. DOI: 10.1254/jjp.74.59. View